It has been suggested that drug repositioning for AD could potentially be facilitated by the conjugation of BBB transporters to various TNF-α inhibitors used for skin diseases or by chemical modification of drugs to increase BBB permeability. The gene discussed is TNF; the disease is Alzheimer disease.